Estimating the value of global investment in immunization programs is critical to helping decision-makers plan and mobilize immunization programs and allocate resources required to realize their full benefits. The recently published ‘Return On Investment From Immunization Against 10 Pathogens In 94 Low- And Middle-Income Countries, 2011–30’ study focuses on the economic benefits of immunization. The researchers use the cost-of-illness and value-of-a-statistical-life approaches, combining this estimation with immunization program costs to derive the return on investment from immunization programs against ten pathogens for 94 low- and middle-income countries for the period 2011–30.
Key insights from the research include the following:
Between 2021 and 2030, immunization programs in 73 low- and middle-income countries will prevent over $782 billion in costs associated with diseases.
Return on investment from immunization programs is estimated to be US$54 per $1 spent when considering value individuals place on their health.
Using a Cost of Illness approach, the estimated net benefit would be about 20 times the cost of immunization programs.
The results demonstrate continued high return on investment from immunization programs. The return-on-investment estimates from this study will inform country policymakers and decision-makers in funding agencies and will contribute to efforts to mobilize resources for immunization. Realization of the full benefits of immunization will depend on sustained investment in and commitment to immunization programs.
Any organization or individual working in the field of immunization economics can submit findings, opportunities, calls to action, or other relevant work below to be shared with our community.